Research programme: antibody therapeutics - Merck & Co
Latest Information Update: 01 Aug 2024
At a glance
- Originator Schering-Plough
- Developer Merck & Co
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 24 Aug 2011 Discontinued - Preclinical for Undefined indication in USA (Parenteral)
- 24 May 2006 Preclinical trials in Undefined indication in USA (Parenteral)